Cargando…

Mining the Mesenchymal Stromal Cell Secretome in Patients with Chronic Left Ventricular Dysfunction

Close examination of the initial results of cardiovascular cell therapy clinical trials indicates the importance of patient-specific differences on outcomes and the need to optimize or customize cell therapies. The fields of regenerative medicine and cell therapy have transitioned from using heterog...

Descripción completa

Detalles Bibliográficos
Autores principales: Morrissey, Jacquelynn, Mesquita, Fernanda C. P., Chacon-Alberty, Lourdes, Hochman-Mendez, Camila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266164/
https://www.ncbi.nlm.nih.gov/pubmed/35805175
http://dx.doi.org/10.3390/cells11132092
_version_ 1784743396336730112
author Morrissey, Jacquelynn
Mesquita, Fernanda C. P.
Chacon-Alberty, Lourdes
Hochman-Mendez, Camila
author_facet Morrissey, Jacquelynn
Mesquita, Fernanda C. P.
Chacon-Alberty, Lourdes
Hochman-Mendez, Camila
author_sort Morrissey, Jacquelynn
collection PubMed
description Close examination of the initial results of cardiovascular cell therapy clinical trials indicates the importance of patient-specific differences on outcomes and the need to optimize or customize cell therapies. The fields of regenerative medicine and cell therapy have transitioned from using heterogeneous bone marrow mononuclear cells (BMMNCs) to mesenchymal stromal cells (MSCs), which are believed to elicit benefits through paracrine activity. Here, we examined MSCs from the BMMNCs of heart failure patients enrolled in the FOCUS-CCTRN trial. We sought to identify differences in MSCs between patients who improved and those who declined in heart function, regardless of treatment received. Although we did not observe differences in the cell profile of MSCs between groups, we did find significant differences in the MSC secretome profile between patients who improved or declined. We conclude that “mining” the MSC secretome may provide clues to better understand the impact of patient characteristics on outcomes after cell therapy and this knowledge can inform future cell therapy trials.
format Online
Article
Text
id pubmed-9266164
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92661642022-07-09 Mining the Mesenchymal Stromal Cell Secretome in Patients with Chronic Left Ventricular Dysfunction Morrissey, Jacquelynn Mesquita, Fernanda C. P. Chacon-Alberty, Lourdes Hochman-Mendez, Camila Cells Opinion Close examination of the initial results of cardiovascular cell therapy clinical trials indicates the importance of patient-specific differences on outcomes and the need to optimize or customize cell therapies. The fields of regenerative medicine and cell therapy have transitioned from using heterogeneous bone marrow mononuclear cells (BMMNCs) to mesenchymal stromal cells (MSCs), which are believed to elicit benefits through paracrine activity. Here, we examined MSCs from the BMMNCs of heart failure patients enrolled in the FOCUS-CCTRN trial. We sought to identify differences in MSCs between patients who improved and those who declined in heart function, regardless of treatment received. Although we did not observe differences in the cell profile of MSCs between groups, we did find significant differences in the MSC secretome profile between patients who improved or declined. We conclude that “mining” the MSC secretome may provide clues to better understand the impact of patient characteristics on outcomes after cell therapy and this knowledge can inform future cell therapy trials. MDPI 2022-06-30 /pmc/articles/PMC9266164/ /pubmed/35805175 http://dx.doi.org/10.3390/cells11132092 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Opinion
Morrissey, Jacquelynn
Mesquita, Fernanda C. P.
Chacon-Alberty, Lourdes
Hochman-Mendez, Camila
Mining the Mesenchymal Stromal Cell Secretome in Patients with Chronic Left Ventricular Dysfunction
title Mining the Mesenchymal Stromal Cell Secretome in Patients with Chronic Left Ventricular Dysfunction
title_full Mining the Mesenchymal Stromal Cell Secretome in Patients with Chronic Left Ventricular Dysfunction
title_fullStr Mining the Mesenchymal Stromal Cell Secretome in Patients with Chronic Left Ventricular Dysfunction
title_full_unstemmed Mining the Mesenchymal Stromal Cell Secretome in Patients with Chronic Left Ventricular Dysfunction
title_short Mining the Mesenchymal Stromal Cell Secretome in Patients with Chronic Left Ventricular Dysfunction
title_sort mining the mesenchymal stromal cell secretome in patients with chronic left ventricular dysfunction
topic Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266164/
https://www.ncbi.nlm.nih.gov/pubmed/35805175
http://dx.doi.org/10.3390/cells11132092
work_keys_str_mv AT morrisseyjacquelynn miningthemesenchymalstromalcellsecretomeinpatientswithchronicleftventriculardysfunction
AT mesquitafernandacp miningthemesenchymalstromalcellsecretomeinpatientswithchronicleftventriculardysfunction
AT chaconalbertylourdes miningthemesenchymalstromalcellsecretomeinpatientswithchronicleftventriculardysfunction
AT hochmanmendezcamila miningthemesenchymalstromalcellsecretomeinpatientswithchronicleftventriculardysfunction